First human test for new nerve disease drug
NCT ID NCT07343310
Summary
This was a small, early-stage study to check if a new drug called KINE-101 is safe for people with a chronic nerve disease called CIDP, when standard steroid treatments haven't worked. Nine patients received a single intravenous dose at one of three increasing levels and were monitored for side effects for 28 days. The main goal was to see how well the body tolerated the drug, not to prove it works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIDP - CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kangbuk Samsung Hospital
Seoul, Seoul, 03181, South Korea
-
Samsung Medical Center
Seoul, Seoul, 06351, South Korea
Conditions
Explore the condition pages connected to this study.